A 45-year-old woman is newly diagnosed with highly active rheumatoid arthritis. She presents with symmetric swelling of her metacarpophalangeal and proximal interphalangeal joints, along with 2 hours of morning stiffness. Radiographs show early marginal erosions. Assuming an inadequate clinical response to each preceding step over several months, arrange the following interventions in the standard sequential order of therapy escalation for the management of her disease.
- 1Initiate monotherapy with a conventional synthetic DMARD (e.g., methotrexate) alongside short-term bridging glucocorticoids.
- 2Add a biologic DMARD, such as a tumor necrosis factor (TNF) inhibitor (e.g., adalimumab).
- 3Switch to a biologic agent with a different mechanism of action (e.g., rituximab) or a targeted synthetic DMARD (e.g., tofacitinib).
- 4Pursue surgical joint intervention, such as total joint arthroplasty.
Answer
The optimal sequence begins with conventional synthetic DMARDs (methotrexate), progresses to the addition of a biologic DMARD (TNF inhibitor), switches to a non-TNF biologic or targeted synthetic DMARD if the first biologic fails, and ultimately reserves surgical intervention for irreversible, end-stage joint destruction.
The standard of care for rheumatoid arthritis escalation follows a logical progression from broad conventional immunosuppression (methotrexate) to targeted biologic agents (TNF inhibitors), followed by alternative targeted mechanisms (non-TNF biologics or JAK inhibitors) if primary resistance occurs, and ends with surgical correction if irreversible structural damage ensues.
Step-by-Step Solution
Key Concept
Stepwise pharmacologic escalation in the management of rheumatoid arthritis.